2025 Q3 -tulosraportti
Vain PDF
30 päivää sitten
Tarjoustasot
Spotlight Stock Market SE
Määrä
Osto
15 000
Myynti
Määrä
15 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 15 000 | NON | AVA | ||
| 34 569 | AVA | AVA | ||
| 6 500 | AVA | NRD | ||
| 5 000 | AVA | NON | ||
| 1 500 | AVA | AVA |
Ylin
0,6VWAP
Alin
0,527VaihtoMäärä
0,4 630 020
VWAP
Ylin
0,6Alin
0,527VaihtoMäärä
0,4 630 020
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 20.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 14.11. | |
| 2025 Q2 -tulosraportti | 19.8. | |
| 2025 Q1 -tulosraportti | 8.5. | |
| 2024 Q4 -tulosraportti | 21.2. | |
| 2024 Q3 -tulosraportti | 29.11.2024 |
Datan lähde: FactSet, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·5.12.It is an insult to the shareholders with the incredibly slow rollout of their product. In the last year, they have only managed to establish sales in the Nordics. The lack of rollout is clearly a management problem, who apparently are unable to get things moving.
·14.11.AcuCort publishes interim report for the third quarter 2025 https://www.acucort.se/sv/acucort-publicerar-delarsrapport-for-tredje-kvartalet-2025/- ·6.11.Managing Director Jonas Jönmark speaks AcuCort is in an intense and exciting phase, where we are laying the foundation for our future growth. I would like to extend a warm thank you to all my employees who make a very strong effort every day. We will also soon further strengthen our team. With Anna Chérouvrier Hansson as Business Development Director, I am fully convinced that AcuCort will advance its positions at an even faster pace. Anna will focus on strengthening and developing our strategic partnerships, a work that will contribute to the launch of Zeqmelit® in several markets and at a faster pace than would otherwise have been possible. She has a solid background and a strong drive with experience from both listed companies and growth companies. Both I and the board are convinced that this combination is an excellent match for AcuCort. In June, we signed two important letters of intent. The agreement with Lunatus covers the Middle East and the Gulf States, while the agreement with Glenmark Pharmaceuticals covers Germany, the Netherlands, the Czech Republic, Austria, Slovakia, and Ukraine. Negotiations are well advanced, and in both cases, due diligence is ongoing in parallel with discussions on the commercial terms. The goal is for both of these to be converted into commercial agreements during the current year. In addition, we are also in dialogue with other major players regarding potential agreements for additional markets. Regarding our dialogue with the FDA, we have answered the questions they sent us, after a previous delay. The FDA then has 90 days to respond. We are in dialogue with the authority and are working to ensure that the FDA keeps its schedule this time. The Nordic launch In the Nordics, Zeqmelit® is launched together with our commercial partner Unimedic Pharma. The launch follows the classic development curve for drug launches: launch phase, growth phase, and maturity phase. In the launch phase, where we are now, we are building sales momentum. This phase can be compared to a train that gradually and steadily increases speed. This is because the healthcare system – and especially prescribing physicians – must first get to know the medicine and start using it in their daily clinical practice. We know that we have the doctors on our side, and that more and more are seeing the benefits of Zeqmelit® in the treatment of allergic reactions. In addition, the medicine's benefits are also recognized in the treatment of croup in young children, where the oral film is completely superior. Then patients will come to the doctors to get Zeqmelit® prescribed, and here too we see increased interest, which gives us a stable starting point for the growth phase. The launch phase thus lays the foundation for the growth phase. The growth phase is characterized by more and more patients and doctors gaining their own experience with the medicine, and patient demand increasing, which often leads to a rapid increase in sales. This is followed by the maturity phase, where sales stabilize at a high level. AcuCort stands strong with an innovative product that is in the launch phase, and an experienced team that drives the internationalization process. In other words, we are in the middle of the phase where the foundation for future growth is being laid. With the right partnership, a strong team, and a medicine that makes a real difference, the direction is clear – forward. Jonas Jönmark , Managing Director, AcuCort
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
Vain PDF
30 päivää sitten
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·5.12.It is an insult to the shareholders with the incredibly slow rollout of their product. In the last year, they have only managed to establish sales in the Nordics. The lack of rollout is clearly a management problem, who apparently are unable to get things moving.
- ·14.11.AcuCort publishes interim report for the third quarter 2025 https://www.acucort.se/sv/acucort-publicerar-delarsrapport-for-tredje-kvartalet-2025/
- ·6.11.Managing Director Jonas Jönmark speaks AcuCort is in an intense and exciting phase, where we are laying the foundation for our future growth. I would like to extend a warm thank you to all my employees who make a very strong effort every day. We will also soon further strengthen our team. With Anna Chérouvrier Hansson as Business Development Director, I am fully convinced that AcuCort will advance its positions at an even faster pace. Anna will focus on strengthening and developing our strategic partnerships, a work that will contribute to the launch of Zeqmelit® in several markets and at a faster pace than would otherwise have been possible. She has a solid background and a strong drive with experience from both listed companies and growth companies. Both I and the board are convinced that this combination is an excellent match for AcuCort. In June, we signed two important letters of intent. The agreement with Lunatus covers the Middle East and the Gulf States, while the agreement with Glenmark Pharmaceuticals covers Germany, the Netherlands, the Czech Republic, Austria, Slovakia, and Ukraine. Negotiations are well advanced, and in both cases, due diligence is ongoing in parallel with discussions on the commercial terms. The goal is for both of these to be converted into commercial agreements during the current year. In addition, we are also in dialogue with other major players regarding potential agreements for additional markets. Regarding our dialogue with the FDA, we have answered the questions they sent us, after a previous delay. The FDA then has 90 days to respond. We are in dialogue with the authority and are working to ensure that the FDA keeps its schedule this time. The Nordic launch In the Nordics, Zeqmelit® is launched together with our commercial partner Unimedic Pharma. The launch follows the classic development curve for drug launches: launch phase, growth phase, and maturity phase. In the launch phase, where we are now, we are building sales momentum. This phase can be compared to a train that gradually and steadily increases speed. This is because the healthcare system – and especially prescribing physicians – must first get to know the medicine and start using it in their daily clinical practice. We know that we have the doctors on our side, and that more and more are seeing the benefits of Zeqmelit® in the treatment of allergic reactions. In addition, the medicine's benefits are also recognized in the treatment of croup in young children, where the oral film is completely superior. Then patients will come to the doctors to get Zeqmelit® prescribed, and here too we see increased interest, which gives us a stable starting point for the growth phase. The launch phase thus lays the foundation for the growth phase. The growth phase is characterized by more and more patients and doctors gaining their own experience with the medicine, and patient demand increasing, which often leads to a rapid increase in sales. This is followed by the maturity phase, where sales stabilize at a high level. AcuCort stands strong with an innovative product that is in the launch phase, and an experienced team that drives the internationalization process. In other words, we are in the middle of the phase where the foundation for future growth is being laid. With the right partnership, a strong team, and a medicine that makes a real difference, the direction is clear – forward. Jonas Jönmark , Managing Director, AcuCort
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market SE
Määrä
Osto
15 000
Myynti
Määrä
15 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 15 000 | NON | AVA | ||
| 34 569 | AVA | AVA | ||
| 6 500 | AVA | NRD | ||
| 5 000 | AVA | NON | ||
| 1 500 | AVA | AVA |
Ylin
0,6VWAP
Alin
0,527VaihtoMäärä
0,4 630 020
VWAP
Ylin
0,6Alin
0,527VaihtoMäärä
0,4 630 020
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 20.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 14.11. | |
| 2025 Q2 -tulosraportti | 19.8. | |
| 2025 Q1 -tulosraportti | 8.5. | |
| 2024 Q4 -tulosraportti | 21.2. | |
| 2024 Q3 -tulosraportti | 29.11.2024 |
Datan lähde: FactSet, Quartr
2025 Q3 -tulosraportti
Vain PDF
30 päivää sitten
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 20.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 14.11. | |
| 2025 Q2 -tulosraportti | 19.8. | |
| 2025 Q1 -tulosraportti | 8.5. | |
| 2024 Q4 -tulosraportti | 21.2. | |
| 2024 Q3 -tulosraportti | 29.11.2024 |
Datan lähde: FactSet, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·5.12.It is an insult to the shareholders with the incredibly slow rollout of their product. In the last year, they have only managed to establish sales in the Nordics. The lack of rollout is clearly a management problem, who apparently are unable to get things moving.
- ·14.11.AcuCort publishes interim report for the third quarter 2025 https://www.acucort.se/sv/acucort-publicerar-delarsrapport-for-tredje-kvartalet-2025/
- ·6.11.Managing Director Jonas Jönmark speaks AcuCort is in an intense and exciting phase, where we are laying the foundation for our future growth. I would like to extend a warm thank you to all my employees who make a very strong effort every day. We will also soon further strengthen our team. With Anna Chérouvrier Hansson as Business Development Director, I am fully convinced that AcuCort will advance its positions at an even faster pace. Anna will focus on strengthening and developing our strategic partnerships, a work that will contribute to the launch of Zeqmelit® in several markets and at a faster pace than would otherwise have been possible. She has a solid background and a strong drive with experience from both listed companies and growth companies. Both I and the board are convinced that this combination is an excellent match for AcuCort. In June, we signed two important letters of intent. The agreement with Lunatus covers the Middle East and the Gulf States, while the agreement with Glenmark Pharmaceuticals covers Germany, the Netherlands, the Czech Republic, Austria, Slovakia, and Ukraine. Negotiations are well advanced, and in both cases, due diligence is ongoing in parallel with discussions on the commercial terms. The goal is for both of these to be converted into commercial agreements during the current year. In addition, we are also in dialogue with other major players regarding potential agreements for additional markets. Regarding our dialogue with the FDA, we have answered the questions they sent us, after a previous delay. The FDA then has 90 days to respond. We are in dialogue with the authority and are working to ensure that the FDA keeps its schedule this time. The Nordic launch In the Nordics, Zeqmelit® is launched together with our commercial partner Unimedic Pharma. The launch follows the classic development curve for drug launches: launch phase, growth phase, and maturity phase. In the launch phase, where we are now, we are building sales momentum. This phase can be compared to a train that gradually and steadily increases speed. This is because the healthcare system – and especially prescribing physicians – must first get to know the medicine and start using it in their daily clinical practice. We know that we have the doctors on our side, and that more and more are seeing the benefits of Zeqmelit® in the treatment of allergic reactions. In addition, the medicine's benefits are also recognized in the treatment of croup in young children, where the oral film is completely superior. Then patients will come to the doctors to get Zeqmelit® prescribed, and here too we see increased interest, which gives us a stable starting point for the growth phase. The launch phase thus lays the foundation for the growth phase. The growth phase is characterized by more and more patients and doctors gaining their own experience with the medicine, and patient demand increasing, which often leads to a rapid increase in sales. This is followed by the maturity phase, where sales stabilize at a high level. AcuCort stands strong with an innovative product that is in the launch phase, and an experienced team that drives the internationalization process. In other words, we are in the middle of the phase where the foundation for future growth is being laid. With the right partnership, a strong team, and a medicine that makes a real difference, the direction is clear – forward. Jonas Jönmark , Managing Director, AcuCort
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market SE
Määrä
Osto
15 000
Myynti
Määrä
15 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 15 000 | NON | AVA | ||
| 34 569 | AVA | AVA | ||
| 6 500 | AVA | NRD | ||
| 5 000 | AVA | NON | ||
| 1 500 | AVA | AVA |
Ylin
0,6VWAP
Alin
0,527VaihtoMäärä
0,4 630 020
VWAP
Ylin
0,6Alin
0,527VaihtoMäärä
0,4 630 020
Välittäjätilasto
Dataa ei löytynyt